Stock Analysis, Dividends, Split History

MHLA / Maiden Holdings Ltd. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,471.64
Enterprise Value ($M)1,654.67
Book Value ($M)1,105.74
Book Value / Share13.30
Price / Book1.33
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 82,974,895
Common Shares Outstanding 83,007,351
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.11
Return on Assets (ROA)-0.03
Return on Equity (ROE)-0.12
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Supplementary Insurance Information Premium Revenue2,732,779,000.00
Net Income-169.75
Earnings Per Share Basic Liabilityfor Unpaid Claimsand Claims Adjustment Expense Period Increase Decrease-1.99
Earnings Per Share Diluted Liabilityfor Unpaid Claimsand Claims Adjustment Expense Period Increase Decrease-1.99
Earnings Per Share Basic-2.32
Earnings Per Share Diluted-2.32
Cash Flow Statement (mra) ($M)
Cash From Operations458.53
Cash from Investing-378.89
Cash from Financing-378.89
Identifiers and Descriptors
Central Index Key (CIK)1412100
Related CUSIPS
G5753U120 G5753U952 0G573U112 036419750

Split History

Stock splits are used by Maiden Holdings Ltd. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Case Study: MHLD's Mistreated 8.6% / 8.3% Yield-To-Worst Baby Bonds

2018-08-09 seekingalpha
Q2 Earnings being just around the corner, I felt like I want to share my thoughts and see what the community thinks.

Green Dot Portfolio: July 2018 Update

2018-08-02 seekingalpha
Realized total return on portfolio investment for July from dividends and swing trades was +1.31% and now totals +9.68% for 9 months. (44-1)

The AmTrust Buyout Could Be a No-Lose Deal for Investors

2018-07-06 investorplace
Shares of commercial insurer AmTrust (NASDAQ:AFSI) were scheduled to open Jul. 3 at $14.60 per share, despite having been approved for sale to private equity at $14.75 per share. (2-0)

Maiden Holdings' Q1 2018: The Upside Potential Remains For This 7% Yielder

2018-05-14 seekingalpha
The company was affected by deteriorated underwriting margins and reported a combined ratio of 101.8% vs. 100.9% one-year ago. (2-0)

Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat

2018-05-11 zacks
Keryx Biopharmaceuticals Inc. (KERX - Free Report) reported a loss of 18 cents per share in the first quarter of 2018, narrower than Zacks Consensus Estimate of a loss of 19 cents. The loss was also narrower than the year-ago loss of 21 cents. (58-0)

CUSIP: G5753U902